Charles River Laboratories Überblick
Branche: Diagnostics & Research
Sektor: Healthcare
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts. Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Mode
Research-Überblick
Letztes Berichtsdatum 2026-08-05Diese Mavefund-Research-Seite bündelt geprüfte Informationen zu Charles River Laboratories (CRL): Unternehmensprofil, Kursverlauf, verknüpfte Primärquellen, verfügbare Finanzberichte, Research-Signale und zu prüfende Risiken.
- Börsennotierung
- CRL · NYSE · MIC XNYS
- Land
- United States
- Handelswährung
- USD
- Branche
- Diagnostics & Research
- Finanzdaten
- Jahres- und Zwischenabschlüsse verfügbar
- Letzte Primärquelle
- SEC EDGAR · veröffentlicht 2026-08-05
- Letzter Bericht · SEC EDGAR Veröffentlicht 2026-08-05
- Registrierungsdokument
Die Abdeckung wird automatisch aktualisiert und erst nach einer Datenintegritätsprüfung veröffentlicht. Nur Research-Unterstützung; keine persönliche Anlageberatung.
Mavefund ordnet die verfügbaren Fundamentaldaten, Bewertungskennzahlen und Risikofaktoren von Charles River Laboratories für einen nachvollziehbaren Research-Prozess ein.
Score
Veröffentlichte Ergebnisse
Was das Unternehmen berichtet hat – mit kompakter Quellenangabe.
Quarterly result summary
Revenue was $1B (reported); EPS was $3.05 (reported).
Was sich verändert hat
- Revenue reported to $1B; EPS reported to $3.05.
- Operating income +20% YoY to $119.9M.
Guidance / outlook
the Company expects the second-quarter investment gains associated with the deferred compensation plan will be largely offset by a higher tax rate, resulting in a negligible net impact to non-GAAP earnings per share.
Source: SEC EDGAR company-filed earnings materials. Dates and source identifiers are retained for verification; review the original filing before relying on extracted report details.
Weitere aktuelle Ergebnisunterlagen
Geprüfte Signal-Evidenz
Aktuelle Nachrichten
Unternehmensrelevante Artikel aus Quellen, die die Relevanz- und Zuverlässigkeitsprüfung des Mave Signals bestehen.
Charles River Laboratories International Inc. stock underperforms Friday when compared to competitors
Headline from MarketWatch: Charles River Laboratories International Inc. stock underperforms Friday when compared to competitors.
Is Wall Street Bullish or Bearish on Charles River Laboratories Stock?
Headline from Yahoo Finance: Is Wall Street Bullish or Bearish on Charles River Laboratories Stock?
Here's How Much $100 Invested In Charles River 15 Years Ago Would Be Worth Today
Headline from Benzinga: Here's How Much $100 Invested In Charles River 15 Years Ago Would Be Worth Today.
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day
Headline from MarketWatch: Charles River Laboratories International Inc. stock outperforms competitors on strong trading day.
Does Charles River (CRL)–Medigen Vaccine Work Sharpen the Case for Its Complex Biologics Edge?
Headline from Yahoo Finance: Does Charles River (CRL)–Medigen Vaccine Work Sharpen the Case for Its Complex Biologics Edge?
Why Is Charles River Laboratories International (CRL) Pushing Deeper Into Vaccine Development?
Headline from Yahoo Finance: Why Is Charles River Laboratories International (CRL) Pushing Deeper Into Vaccine Development?
Gewinn je Aktie
Eigenkapitalrendite
Eigenkapitalrendite
Unternehmen —
Sektormedian —
Eigenkapitalrendite
Unternehmen —
Sektormedian —
Eigenkapitalrendite
Unternehmen —
Sektormedian —
Eigenkapitalrendite
Unternehmen —
Sektormedian —
Kennzahlen-Chart vorübergehend nicht verfügbar.
Nettomarge
Nettomarge
Unternehmen —
Sektormedian —
Nettomarge
Unternehmen —
Sektormedian —
Nettomarge
Unternehmen —
Sektormedian —
Nettomarge
Unternehmen —
Sektormedian —
Kennzahlen-Chart vorübergehend nicht verfügbar.
Verschuldung
Verschuldungsgrad
Unternehmen —
Sektormedian —
Verschuldungsgrad
Unternehmen —
Sektormedian —
Verschuldungsgrad
Unternehmen —
Sektormedian —
Verschuldungsgrad
Unternehmen —
Sektormedian —
Kennzahlen-Chart vorübergehend nicht verfügbar.
Finanzberichte
Vom Unternehmen veröffentlichte Berichtsdaten, strukturiert und mit der Originalquelle verknüpft.
Quellendetails werden mit den Berichtsdaten geladen. Die Werte sind standardisierte Unternehmensangaben zur Research-Unterstützung, keine persönliche Anlageberatung.